Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators.

Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23.

PMID:
31447077
2.

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe.

Prendergast AJ, Berejena C, Pimundu G, Shonhai A, Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Cook AD, Spyer MJ, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Klein N, Walker AS.

AIDS. 2019 Jul 15;33(9):1485-1490. doi: 10.1097/QAD.0000000000002231.

PMID:
31008797
3.

Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.

Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N; CHAPAS-3 Trial Team.

J Infect Dis. 2019 Jan 1;219(1):89-100. doi: 10.1093/infdis/jiy495.

4.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ.

Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.

5.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, Raja FA, Swart AMW, Velikova G, Qian W, Ledermann JA.

Cancer. 2017 Jul 15;123(14):2752-2761. doi: 10.1002/cncr.30657. Epub 2017 Mar 24.

6.

Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.

Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, Debanne S, Klein N, McComsey GA.

Pediatr Infect Dis J. 2017 Aug;36(8):761-767. doi: 10.1097/INF.0000000000001544.

7.

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

AIDS. 2017 Apr 24;31(7):905-915. doi: 10.1097/QAD.0000000000001376.

8.

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.

Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P.

J Antimicrob Chemother. 2017 Jan;72(1):190-199. Epub 2016 Oct 5.

9.

The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.

Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M.

Value Health. 2016 Jun;19(4):431-9. doi: 10.1016/j.jval.2016.01.013. Epub 2016 Mar 24.

10.

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.

11.

Once vs twice-daily abacavir and lamivudine in African children.

Musiime V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, Mhute T, Cook A, Mugarura L, Munjoma M, Thoofer NK, Ndashimye E, Nankya I, Spyer MJ, Thomason MJ, Snowden W, Gibb DM, Walker AS; ARROW Trial Team.

AIDS. 2016 Jul 17;30(11):1761-70. doi: 10.1097/QAD.0000000000001116.

12.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB; ICON6 collaborators.

Lancet. 2016 Mar 12;387(10023):1066-1074. doi: 10.1016/S0140-6736(15)01167-8. Erratum in: Lancet. 2016 Apr 23;387(10029):1722.

13.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P.

Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.

14.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team.

Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.

15.

Discordance between the results and conclusions of ICON7 - Authors' reply.

Oza AM, Cook AD, Kaplan R, Parmar MK, Perren TJ; ICON7 investigators.

Lancet Oncol. 2015 Oct;16(13):e478-9. doi: 10.1016/S1470-2045(15)00311-3. No abstract available.

PMID:
26433820
16.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

17.

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.

Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunyena J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team.

Antivir Ther. 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25.

PMID:
24717427
18.

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM; CHAPAS-1 trial team.

AIDS. 2013 Aug 24;27(13):2111-5. doi: 10.1097/QAD.0b013e3283620811.

PMID:
23595153
19.

Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe.

Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team.

Pediatr Infect Dis J. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991.

PMID:
23407100
20.

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM.

AIDS. 2012 Sep 10;26(14):1795-800. doi: 10.1097/QAD.0b013e32835705fd.

PMID:
22739394
21.

Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa.

Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, Tezikyabbiri J, Naidoo-James B, Gibb D; ARROW Trial Team.

PLoS One. 2012;7(5):e36186. doi: 10.1371/journal.pone.0036186. Epub 2012 May 2.

22.

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.

Oudijk JM, McIlleron H, Mulenga V, Chintu C, Merry C, Walker AS, Cook A, Gibb DM, Burger DM.

AIDS. 2012 Jul 31;26(12):1523-8. doi: 10.1097/QAD.0b013e3283550e20.

PMID:
22546991
23.

Effect of 25 weeks probiotic supplementation on immune function of HIV patients.

Hummelen R, Changalucha J, Butamanya NL, Koyama TE, Cook A, Habbema JD, Reid G.

Gut Microbes. 2011 Mar-Apr;2(2):80-5. Epub 2011 Mar 1.

PMID:
21637031
24.

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.

Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, Kityo C, Thomason M, Kabamba D, Chintu C, Gibb DM, Bangsberg DR.

PLoS One. 2011 Apr 21;6(4):e18505. doi: 10.1371/journal.pone.0018505.

25.

Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy.

Prendergast A, Bwakura-Dangarembizi MF, Cook AD, Bakeera-Kitaka S, Natukunda E, Nahirya Ntege P, Nathoo KJ, Karungi C, Lutaakome J, Kekitiinwa A, Gibb DM.

AIDS. 2011 Apr 24;25(7):951-6. doi: 10.1097/QAD.0b013e328345e56b.

PMID:
21487251
26.

Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV.

Hummelen R, Changalucha J, Butamanya NL, Cook A, Habbema JD, Reid G.

Int J Gynaecol Obstet. 2010 Dec;111(3):245-8. doi: 10.1016/j.ijgo.2010.07.008.

PMID:
20801446
27.

Ethnic variations in the experiences of mental health service users in England: results of a national patient survey programme.

Raleigh VS, Irons R, Hawe E, Scobie S, Cook A, Reeves R, Petruckevitch A, Harrison J.

Br J Psychiatry. 2007 Oct;191:304-12.

PMID:
17906240
28.

Scientific evaluation of community-based Parkinson's disease nurse specialists on patient outcomes and health care costs.

Hurwitz B, Jarman B, Cook A, Bajekal M.

J Eval Clin Pract. 2005 Apr;11(2):97-110.

PMID:
15813708
29.

Making cycle helmets compulsory: ethical arguments for legislation.

Sheikh A, Cook A, Ashcroft R.

J R Soc Med. 2004 Jun;97(6):262-5. No abstract available.

30.

Erectile dysfunction: NHS should meet current need before preventing future medical needs.

Hurwitz B, Cook A, Ashcroft R.

BMJ. 2003 Mar 15;326(7389):598. No abstract available.

31.

A 5-star system for rating the quality of information based on DISCERN.

Shepperd S, Charnock D, Cook A.

Health Info Libr J. 2002 Dec;19(4):201-5.

32.
33.

Statistical Notes VII: Managing Data.

Cook A, Sheikh A.

Prim Care Respir J. 2001 Sep;10(3):71-72. doi: 10.1038/pcrj.2001.23. Epub 2001 Sep 1. No abstract available.

34.

Statistical Notes VI: Study Design.

Sheikh A, Cook A.

Prim Care Respir J. 2001 Jun;10(2):50-51. doi: 10.1038/pcrj.2001.14. Epub 2001 Jun 1. No abstract available.

35.

Statistical Notes V: Sample size calculations.

Cook A, Sheikh A.

Prim Care Respir J. 2001 Mar;10(1):15-16. doi: 10.1038/pcrj.2001.5. Epub 2001 Mar 1. No abstract available.

36.

Estimation: Understanding Confidence Intervals.

Cook A, Sheikh A.

Prim Care Respir J. 2000 Dec;9(3):48-50. doi: 10.1038/pcrj.2000.18. Epub 2000 Dec 1. No abstract available.

37.

Hypothesis testing.

Sheikh A, Cook A.

Prim Care Respir J. 2000 Jun;9(1):16-17. doi: 10.1038/pcrj.2000.11. Epub 2000 Jun 1. No abstract available.

Supplemental Content

Loading ...
Support Center